Physician profile
Cas M Cader
NPI 1356376503
$9,884.28
in general payments reported to CMS, 2019-2025
59 companies · $1,527 in 2025
The $1,527 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $891 · 2020: $554 · 2021: $1,503 · 2022: $1,815 · 2023: $1,807 · 2024: $1,788 · 2025: $1,527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,120.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,269.27 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,176.07 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $1,111.02 | 2019-2025 | Evenity, Prolia, Otezla |
| Glaxosmithkline, LLC. | $827.19 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $651.04 | 2019-2025 | |
| Lilly USA, LLC | $578.61 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $474.58 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbott Laboratories | $378.58 | 2021-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $278.56 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $261.52 | 2020-2025 | Gardasil 9, Capvaxive, Gardasil |
| Preventric Diagnostics, INC. | $222.85 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.37 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $207.62 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $198.80 | 2019-2025 | Trintellix |
| Kowa Pharmaceuticals America, INC. | $135.62 | 2019-2023 | Livalo, Seglentis |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cas Cader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.